Wall Street Zen Upgrades X4 Pharmaceuticals (NASDAQ:XFOR) to “Hold”

X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

XFOR has been the topic of several other research reports. Stifel Nicolaus set a $7.50 price target on shares of X4 Pharmaceuticals in a research report on Wednesday, November 5th. HC Wainwright set a $3.50 price target on X4 Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Tuesday. Finally, Zacks Research upgraded shares of X4 Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.67.

X4 Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ:XFOR opened at $3.75 on Friday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 5.48 and a current ratio of 5.65. X4 Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $26.83. The business’s 50 day simple moving average is $3.46 and its two-hundred day simple moving average is $2.97. The firm has a market cap of $327.90 million, a P/E ratio of -0.37 and a beta of 0.51.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.10. The company had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $2.05 million. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%. As a group, research analysts forecast that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Chairman Adam R. Craig acquired 86,206 shares of the firm’s stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average price of $2.90 per share, for a total transaction of $249,997.40. Following the completion of the acquisition, the chairman owned 376,087 shares of the company’s stock, valued at approximately $1,090,652.30. This represents a 29.74% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.37% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several large investors have recently modified their holdings of XFOR. Bank of America Corp DE boosted its holdings in shares of X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in X4 Pharmaceuticals by 9.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock worth $114,000 after purchasing an additional 43,320 shares in the last quarter. Pale Fire Capital SE boosted its stake in X4 Pharmaceuticals by 45.2% in the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock worth $481,000 after purchasing an additional 633,398 shares during the period. Kingdon Capital Management L.L.C. grew its holdings in X4 Pharmaceuticals by 41.8% during the 1st quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock valued at $1,655,000 after buying an additional 2,063,000 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after buying an additional 9,690 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.